Impacts of Nanomedicines in Ocular Pharmacotherapy

Introduction: The integrity of the cells/tissues in anterior and/or posterior segments of the eye plays a crucial role in biofunctions of the vision. To maintain ocular homeostasis, selective restrictiveness of the ophthalmic membranes and barriers control must act on shuttling of biomolecules. Thus...

Full description

Bibliographic Details
Main Authors: Jaleh Barar, Ailar Nakhlband
Format: Article
Language:English
Published: Tabriz University of Medical Sciences 2011-06-01
Series:BioImpacts
Subjects:
Online Access:http://dx.doi.org/10.5681/bi.2011.003
id doaj-8d1037ec816c412bb9c67bb18d72b22d
record_format Article
spelling doaj-8d1037ec816c412bb9c67bb18d72b22d2020-11-25T00:10:21ZengTabriz University of Medical SciencesBioImpacts2228-56522228-56602011-06-0111722Impacts of Nanomedicines in Ocular PharmacotherapyJaleh BararAilar NakhlbandIntroduction: The integrity of the cells/tissues in anterior and/or posterior segments of the eye plays a crucial role in biofunctions of the vision. To maintain ocular homeostasis, selective restrictiveness of the ophthalmic membranes and barriers control must act on shuttling of biomolecules. Thus, not all attempts to apply de novo nanotechnology approaches for ocular pharmacotherapy have met with the same successes as those cited here in this review, and sometimes these novel technologies tools provoke a great deal of challenges and hurdles mainly because of functional presence of these barriers. Methods: Recent published articles related to application of ocular nanomedicines were reviewed and highlighted in this review article. Results: It seems the emergence of nanomedicines have arisen great hopes for ophthalmic pharmacotherapy, in which nanostructured medicines are expected to be able to cross the restrictive barriers of the eye. Although such fast inauguration of ocular nanomedicines will literally convey new challenges in the regulatory and translational processes, it will also grant a prolific platform from which many exciting, and yet unimagined, applications of biomedical nanotechnology will emerge for pharmacotherapy of the eye. Conclusion: This review provide recent advancements on ocular nanomedicines.http://dx.doi.org/10.5681/bi.2011.003Molecular MedicineNanotechnologyNanomedicineOcular Drug DeliveryOphthalmology
collection DOAJ
language English
format Article
sources DOAJ
author Jaleh Barar
Ailar Nakhlband
spellingShingle Jaleh Barar
Ailar Nakhlband
Impacts of Nanomedicines in Ocular Pharmacotherapy
BioImpacts
Molecular Medicine
Nanotechnology
Nanomedicine
Ocular Drug Delivery
Ophthalmology
author_facet Jaleh Barar
Ailar Nakhlband
author_sort Jaleh Barar
title Impacts of Nanomedicines in Ocular Pharmacotherapy
title_short Impacts of Nanomedicines in Ocular Pharmacotherapy
title_full Impacts of Nanomedicines in Ocular Pharmacotherapy
title_fullStr Impacts of Nanomedicines in Ocular Pharmacotherapy
title_full_unstemmed Impacts of Nanomedicines in Ocular Pharmacotherapy
title_sort impacts of nanomedicines in ocular pharmacotherapy
publisher Tabriz University of Medical Sciences
series BioImpacts
issn 2228-5652
2228-5660
publishDate 2011-06-01
description Introduction: The integrity of the cells/tissues in anterior and/or posterior segments of the eye plays a crucial role in biofunctions of the vision. To maintain ocular homeostasis, selective restrictiveness of the ophthalmic membranes and barriers control must act on shuttling of biomolecules. Thus, not all attempts to apply de novo nanotechnology approaches for ocular pharmacotherapy have met with the same successes as those cited here in this review, and sometimes these novel technologies tools provoke a great deal of challenges and hurdles mainly because of functional presence of these barriers. Methods: Recent published articles related to application of ocular nanomedicines were reviewed and highlighted in this review article. Results: It seems the emergence of nanomedicines have arisen great hopes for ophthalmic pharmacotherapy, in which nanostructured medicines are expected to be able to cross the restrictive barriers of the eye. Although such fast inauguration of ocular nanomedicines will literally convey new challenges in the regulatory and translational processes, it will also grant a prolific platform from which many exciting, and yet unimagined, applications of biomedical nanotechnology will emerge for pharmacotherapy of the eye. Conclusion: This review provide recent advancements on ocular nanomedicines.
topic Molecular Medicine
Nanotechnology
Nanomedicine
Ocular Drug Delivery
Ophthalmology
url http://dx.doi.org/10.5681/bi.2011.003
work_keys_str_mv AT jalehbarar impactsofnanomedicinesinocularpharmacotherapy
AT ailarnakhlband impactsofnanomedicinesinocularpharmacotherapy
_version_ 1725408013514178560